Testing first-line antibody plus immunotherapy for mediastinal lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary mediastinal large B-cell lymphoma confirmed by tumor tissue testing
- Your tumor shows CD30 in at least 1% of cells (checked by local lab testing)
- You have not had prior lymphoma treatment (except limited radiation, or a short steroid burst up to 7 days before starting)
- You must be at least 18, and your lymphoma must be measurable on scans (at least 1.5 cm longest size)
- Your blood counts and organ tests must be adequate (including enough neutrophils, platelets, and kidney/liver function)
- You must be able and willing to sign consent and to receive blood transfusions if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a fixed low dose of nivolumab combined with standard chemo-immunotherapy for people newly diagnosed with primary mediastinal B-cell lymphoma. The goal is to see if this combination is safe and effective.
This trial is testing a new combination of immunotherapy (sintilimab and rituximab) followed by standard chemotherapy (R-CHOP) for people with untreated primary mediastinal B-cell lymphoma (PMBCL). It aims to see if this approach can improve outcomes for this specific type of lymphoma.
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
This trial tests a new sequence of chemotherapy drugs for people with intermediate-to-high risk diffuse large B-cell lymphoma who did not achieve complete remission after their first two cycles of standard treatment. The goal is to see if this approach is safe and effective.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests a combination of two drugs (brentuximab vedotin, AVD chemotherapy) for people with newly diagnosed, bulky Hodgkin lymphoma that hasn't spread far. It aims to see if this treatment works well for larger tumors.
Hear when a new Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.